At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
dimebon +5 moredrug
Likely dose
dimebon 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
In Brief
A Phase 1 clinical trial evaluating dimebon, placebo, and 1 other intervention for Alzheimer's Disease and Huntington's Disease. Completed, enrolled 36 participants.
Detailed Summary
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Huntington's Disease
Countries--
CollaboratorsMedivation, Inc.
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedSep 11, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.8 years ago
Interventions
dimebondrug
Oral tablet; 20 mg dimebon, single dose
dimebondrug
Oral tablet; 40 mg dimebon, single dose
dimebondrug
Oral tablet; 60 mg dimebon, single dose
placebodrug
Oral tablet or capsule; placebo, single dose
alprazolamdrug
Oral capsule; 1 mg alprazolam, single dose
alprazolamdrug
Oral capsule; 3 mg alprazolam, single dose